dissolution

ABSTRACTLiquisolid strategy is otherwise called powder solution technology. It is the system which manages the solubility upgrade of inadequately solvent medications. As nowadays there are numerous medications in the market with poor solvency which prompts poor disintegration and bioavailability, so dissolvability is getting to be rate constraining component in the advancement of new medications. To defeat this issue there are numerous systems yet liquisolid strategy is most encouraging procedure which is talked about in this article. Liquisolid is for the most part made out of medication, non volatile solvent, carrier material, coating material, and disintegrant. In liquisolid strategy carrier and coating material which ought to be in the proportion of 20:1 is blended into the non volatile solvent and after that disintegrant is included and last material is packed into tablets. Henceforth, the liquisolid innovation permits the change of fluid frameworks into strong medication conveyance frameworks. Both quick and managed arrival of medication can likewise be accomplished with the assistance of liquisolid procedure. For sustained release of medication hydrophilic polymer like Hydroxy Propyl Methyl Cellulose can be the best choice. The motivation behind this article is to depict about the liquisolid strategy like basics, classification, preformulation examines, characterization, pre compression contemplates, detailing of tablet, post compression thinks about, points of interest, drawbacks, applications.Keywords: Liquisolid, bioavailability, dissolution, sustained release.

The objective of the study was to increase the stability, and dissolution rate of Rosuvastatin Calcium, an acid labile antihyperlipedemic drug which acts as 3-hydroxy3-methyl glut aryl CoA (HMG-CoA) Reductase inhibitor through incorporation of different alkalizers. The different alkalizers used in the study are trisodium citrate, sodium bicarbonate, sodium alginate, di sodium hydrogen phosphate and meglumine. The tablets are prepared by direct compression and wet granulation method. The prepared tablets were evaluated for various post compression parameters like hardness, friability, weight variation, thickness, drug content and in-vitro dissolution. The results of the study revealed that the organic monovalent alkaliser meglumine shows the best results when compared with the innovator formulation. The dissolution studies showed that the drug release from all the formulation was complete and uniform in pH 6.6 sodium citrate buffer and T12 hardness (8.2 ±0.6) kp ,thickness(4.18 ±0.12)mm, friability (0.44)%, drug content uniformity (102±0.9)% and dissolution profile(99.5%) shows near to that of innovator and found to be the best formulation showing the drug release matched with that of innovator. The stability of tablets was studied at 40°C & 75%RH for period of 3 months at 40°C & 75% RH and no significant changes were detected in the hardness, friability, assay and dissolution profile of tablets after 3 month. The release kinetics studies performed and it follows the first order release kinetics and Peppas model indicates the mechanism of drug release i.e. Fickian diffusion. From the study it can be concluded that the formulation T12 can be considered as the optimized formulation. Key words: Anti hyper lipidemic, alkaliser, dissolution, stability.